- A new vaccine, ELI-002 2P, shows promise in slowing the progression of pancreatic and bowel cancers, with researchers suggesting it could be manufactured in bulk.
- A trial involving 20 pancreatic cancer patients and five bowel cancer patients found that 68 per cent developed strong immune responses to KRAS-mutant tumour proteins.
- Participants with stronger immune responses lived longer and remained cancer-free for extended periods, with patients surviving about two years and five months after vaccination.
- The jab, which uses a new type of immunotherapy, also demonstrated the potential to prevent cancer recurrence for over 15 months, a significant improvement for cancers with poor survival rates.
- While Cancer Research UK highlights the promising results and the potential for improved survival, some experts caution that larger, controlled trials are needed to confirm its clinical utility.
IN FULL
